MEDTECH INDUSTRY INVITED TO NSW PARLIAMENT HOUSE Local manufacturing emerges as key priority, along with jobs, supply chain resilience and patient benefits
With
Justin Foster,
Associate Director, Advocacy and Government Relations,
Medical Technology Association of Australia
Brendan Cummins
VP & General Manager ANZ,
Baxter Healthcare
The Hon Courtney Houssos MLC, Minister for Finance,
Minister for Domestic Manufacturing and Government Procurement,
Minister for Natural Resources, NSW Parliament
James Doyle, Vice-Chair
Medical Technology Association of Australia (MTAA)
Lachlan Thorpe, Age 21
Diagnosed with CRPS following sporting injury, recipient of spinal cord stimulator
SEGMENT
Filmed in Sydney | August 2026
The inaugural NSW Parliament MedTech Showcase, hosted by The Hon Courtney Houssos MLC has highlighted the medical technology sector’s contribution to patient care, local manufacturing, jobs and the broader economy.
Speaking with the Australian Health Journal, Justin Foster, Associate Director of Advocacy and Government Relations at the Medical Technology Association of Australia (MTAA), said the event provided an important opportunity for industry and government to work together on shared priorities.
He said the showcase demonstrated that MedTech not only saves and improves lives, but also creates significant economic opportunities through manufacturing, investment, exports and employment. “We’re collaborating with them on a unity ticket in terms of delivering more value to the economy, manufacturing, and also to local jobs,” Foster said.
The event brought together a diverse range of companies, from emerging startups and small and medium-sized businesses to global MedTech companies investing in NSW. The showcase also demonstrated the importance of sovereign manufacturing capability, particularly during supply disruptions.
The message was local production could strengthen supply chains while supporting highly skilled employment and innovation. The event also provided an opportunity for the industry to discuss policy issues, including value-based procurement, which seeks to ensure purchasing decisions consider the broader value of medical technologies rather than price alone.
Foster said the showcase could serve as a model for further engagement across Australia. “There is definitely an opportunity for us to be engaging across states and territories,” with future discussions potentially extending the initiative beyond NSW.
Source: Written by Australian Health Journal from transcript.
-
Challenge advances health technologies and medical devices in the MedTech sector
In July IDE Group launched the 2027 Building Better Futures for Health (BBFH) Challenge, a program supporting early-stage MedTech innovators move from concept to commercialisation. Delivered with Medical Technology Association of Australia’s (MTAA) MedTech Compass, the 2027 program marks 10 years of impact.
Now in its 11th year, BBFH supports researchers, clinicians, entrepreneurs and early-stage ventures tackling urgent healthcare needs. Selected teams will pitch to industry experts, gaining feedback to strengthen commercial potential.
-
Surgeon receives global award for kidney transplant science
Commencing a new series called Pioneers in Health Care, is an interview with Professor Jeremy Chapman AC who for over 40 years, has been involved in nephrectomy, or kidney transplantation.
Honoured “for eminent service to medicine, particularly in the areas of clinical and biomedical research, to the development of ethical policy and practices for organ donation, acquisition and transplantation, and to renal medicine organisations and publications, Jeremy Chapman AC has played significant roles in development of kidney, pancreas and unrelated Bone Marrow Transplantation in Australia. -
New option for management of high-risk soft tissue sarcoma of the limb
SARC032 is the first completed randomised clinical trial of its kind and has demonstrated compelling evidence to integrate immunotherapy, with the standard treatment regimen of radiotherapy and surgery for patients with grade 2 or 3, stage III soft tissue sarcoma of the limb.
